Ann: US CPT Code Reimbursement for TALi Detect, page-394

Here's from the 2019 annual report released this week,

"Likely developments, outlook and risks

The Company’s focus for the coming year will be to integrate TALi TRAIN and TALi DETECT into a commercially suitable platform under the brand name “Ready, Attention, Go” in order to become a global leader in the assessment and treatment of children in the area of inattention. The Company has also completed the divestment of Newly in order to support the mission of the Company to deliver market leading, patient outcome focused digital interventions.

Novita Healthcare’s lead product, TALi TRAIN is a program is scientifically and clinically proven to improve attention as
a cognitive skill by targeting the core underlying issue which sets it apart from all other brain training or memory-based
software applications., and provides a much-needed adjunct to pharmacological treatments. TALi DETECT is currently
in final development and late stages of a randomised controlled clinical trial with the launch of the assessment tool
expected in October 2019.

Novita Healthcare’s lead product, TALi TRAIN is a digital cognitive training program which was released in the Australian market during FY2018/2019. The program uniquely targets core areas of weakness in children with developmental delay via a digital game-based software application, and provides a much-needed adjunct or alternative to pharmacological
treatments. The claims of the program are underpinned by strong clinical trial data with trials conducted through Monash
University. These clinical trials demonstrated that the product was successful in promoting improvements in both attention (in particular the ability to focus on relevant information while ignoring distractions) and academic skills (specifically numeracy abilities) in young children with developmental delay, including those with autism spectrum disorder (ASD)
The ability of the Group to meet operating cash requirements for the next 12 months has been secured by an Entitlement
Offer to shareholders raising a total of $2.0 million (as announced to ASX on 19 September 2019) which will be added
to the existing cash on hand of $0.3 million at the year end. Beyond the next 12 months, the Group expects cash flows
being generated from the successful execution of the TALi commercialisation strategy and development opportunities will support the cash position of the Company. The TALi commercialisation strategy is dependent on a number of factors including, among others, assumptions relating to development and marketing expenditure, market demand, sales volume and pricing, working capital requirements and regulatory compliance.


TALi HEALTH Pty Ltd
TALi HEALTH, (100% owned subsidiary of Novita Healthcare) is a med-tech company pioneering development of software solutions to address neurological conditions in early childhood. Backed by over 25 years of research, the TALi
platform is a scientific and clinically validated program that addresses the world’s leading early childhood issue—
inattention, a key feature in conditions including ADHD and ASD). Our team of neuroscientists, developers and designers
are on a mission to strengthen the attention of children globally to deliver a lasting social impact.

At TALi, happier kids start here. Approximately 126 million children globally have severe attention difficulties. The key to better outcomes for children with attention difficulties is early identification and intervention. Currently, there is a significant lack of tools available to parents, teachers and healthcare professional to provide effective assessment and treatment. Consequently, many children who have attention difficulties remain undetected and miss out on life-changing interventions. TALi DETECT and TALi TRAIN as early assessment and training programs are early intervention programs designed to change that.

TALi focuses on assessing potential attention issues and then if required strengthening underlying attentional processes at the cognitive level. Thus, TALi has the potential to promote deeper and more stable improvements in attention, as
well as behavioural symptoms of attention (e.g. inattentive and hyperactive behaviour), without the negative side effects associated with psychostimulant medication. In addition, TALi provides logistical advantages over traditional face to face intervention methods as it uses the latest technology to deliver health care into the home providing significant cost savings and better outcomes for children."